Ascendis Pharma/$ASND
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Ticker
- $ASND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,189
- Headquarters
- Hellerup, Denmark
- Website
- ascendispharma.com
Ascendis Pharma Metrics
BasicAdvanced
$18B
19.91
$13.62
-
-
Price and volume
Market cap
$18B
52-week high
$282.15
52-week low
$203.80
Average daily volume
525K
Financial strength
Current ratio
2.991
Quick ratio
2.229
Long term debt to equity
26.776
Total debt to equity
31.331
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
306.284
Gross margin (TTM)
91.30%
Net profit margin (TTM)
70.84%
Operating margin (TTM)
24.70%
Effective tax rate (TTM)
-658.14%
Revenue per employee (TTM)
$1,023,060
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
118.78%
Valuation
Price to earnings (TTM)
19.905
Price to revenue (TTM)
13.808
Price to book
12.4
Price to tangible book (TTM)
12.43
Price to free cash flow (TTM)
43.141
Free cash flow yield (TTM)
2.32%
Free cash flow per share (TTM)
6.284
Growth
Revenue change (TTM)
113.35%
Earnings per share change (TTM)
-356.73%
3-year revenue growth (CAGR)
106.35%
10-year revenue growth (CAGR)
66.26%
3-year earnings per share growth (CAGR)
2.54%
10-year earnings per share growth (CAGR)
18.61%
Ascendis Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.